Protective Effect of UDCA Against IL-11- Induced Cardiac Fibrosis is Mediated by TGR5 Signalling

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2024 Dec 18

PMID 39691494

Authors

B Reilly-ODonnell

E Ferraro

R Tikhomirov

R Nunez-Toldra

A Shchendrygina

L Patel

Y Wu

A L Mitchell

A Endo

L Adorini

R A Chowdhury

P K Srivastava

F S Ng

C Terracciano

C Williamson

J Gorelik

Affiliations

Soon will be listed here.

Abstract

Introduction: Cardiac fibrosis occurs in a wide range of cardiac diseases and is characterised by the transdifferentiation of cardiac fibroblasts into myofibroblasts these cells produce large quantities of extracellular matrix, resulting in myocardial scar. The profibrotic process is multi-factorial, meaning identification of effective treatments has been limited. The antifibrotic effect of the bile acid ursodeoxycholic acid (UDCA) is established in cases of liver fibrosis however its mechanism and role in cardiac fibrosis is less well understood.

Methods: In this study, we used cellular models of cardiac fibrosis and living myocardial slices to characterise the macroscopic and cellular responses of the myocardium to UDCA treatment. We complemented this approach by conducting RNA-seq on cardiac fibroblasts isolated from dilated cardiomyopathy patients. This allowed us to gain insights into the mechanism of action and explore whether the IL-11 and TGFβ/WWP2 profibrotic networks are influenced by UDCA. Finally, we used fibroblasts from a TGR5 KO mouse to confirm the mechanism of action.

Results And Discussion: We found that UDCA reduced myofibroblast markers in rat and human fibroblasts and in living myocardial slices, indicating its antifibrotic action. Furthermore, we demonstrated that the treatment of UDCA successfully reversed the profibrotic IL-11 and TGFβ/WWP2 gene networks. We also show that TGR5 is the most highly expressed UDCA receptor in cardiac fibroblasts. Utilising cells isolated from a TGR5 knock-out mouse, we identified that the antifibrotic effect of UDCA is attenuated in the KO fibroblasts. This study combines cellular studies with RNA-seq and state-of-the-art living myocardial slices to offer new perspectives on cardiac fibrosis. Our data confirm that TGR5 agonists, such as UDCA, offer a unique pathway of action for the treatment of cardiac fibrosis. Medicines for cardiac fibrosis have been slow to clinic and have the potential to be used in the treatment of multiple cardiac diseases. UDCA is well tolerated in the treatment of other diseases, indicating it is an excellent candidate for further in-human trials.

References

Corden B, Adami E, Sweeney M, Schafer S, Cook S . IL-11 in cardiac and renal fibrosis: Late to the party but a central player. Br J Pharmacol. 2020; 177(8):1695-1708. PMC: 7070163. DOI: 10.1111/bph.15013. View

Frantz S, Falcao-Pires I, Balligand J, Bauersachs J, Brutsaert D, Ciccarelli M . The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC. Eur J Heart Fail. 2018; 20(3):445-459. PMC: 5993315. DOI: 10.1002/ejhf.1138. View

Santos-Gallego C, Requena-Ibanez J, Antonio R, Garcia-Ropero A, Ishikawa K, Watanabe S . Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure: A Multimodality Study. JACC Cardiovasc Imaging. 2020; 14(2):393-407. DOI: 10.1016/j.jcmg.2020.07.042. View

Robinson M, McCarthy D, Smyth G . edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2009; 26(1):139-40. PMC: 2796818. DOI: 10.1093/bioinformatics/btp616. View

Ye H, Zhang J, Chen X, Wu P, Chen L, Zhang G . Ursodeoxycholic acid alleviates experimental liver fibrosis involving inhibition of autophagy. Life Sci. 2019; 242:117175. DOI: 10.1016/j.lfs.2019.117175. View

Alqudah M, Hale T, Czubryt M . Targeting the renin-angiotensin-aldosterone system in fibrosis. Matrix Biol. 2020; 91-92:92-108. PMC: 7434656. DOI: 10.1016/j.matbio.2020.04.005. View

de Boer R, Meijers W, van der Meer P, Van Veldhuisen D . Cancer and heart disease: associations and relations. Eur J Heart Fail. 2019; 21(12):1515-1525. PMC: 6988442. DOI: 10.1002/ejhf.1539. View

Watson S, Scigliano M, Bardi I, Ascione R, Terracciano C, Perbellini F . Preparation of viable adult ventricular myocardial slices from large and small mammals. Nat Protoc. 2017; 12(12):2623-2639. DOI: 10.1038/nprot.2017.139. View

Williamson C, Gorelik J, Eaton B, Lab M, de Swiet M, Korchev Y . The bile acid taurocholate impairs rat cardiomyocyte function: a proposed mechanism for intra-uterine fetal death in obstetric cholestasis. Clin Sci (Lond). 2001; 100(4):363-9. View

10.

von Haehling S, Schefold J, Jankowska E, Springer J, Vazir A, Kalra P . Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial. J Am Coll Cardiol. 2012; 59(6):585-92. DOI: 10.1016/j.jacc.2011.10.880. View

11.

Sato H, Macchiarulo A, Thomas C, Gioiello A, Une M, Hofmann A . Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. J Med Chem. 2008; 51(6):1831-41. DOI: 10.1021/jm7015864. View

12.

Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M . A G protein-coupled receptor responsive to bile acids. J Biol Chem. 2003; 278(11):9435-40. DOI: 10.1074/jbc.M209706200. View

13.

Cheung A, Lapointe-Shaw L, Kowgier M, Meza-Cardona J, Hirschfield G, Janssen H . Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. Aliment Pharmacol Ther. 2015; 43(2):283-93. DOI: 10.1111/apt.13465. View

14.

Plikus M, Wang X, Sinha S, Forte E, Thompson S, Herzog E . Fibroblasts: Origins, definitions, and functions in health and disease. Cell. 2021; 184(15):3852-3872. PMC: 8566693. DOI: 10.1016/j.cell.2021.06.024. View

15.

Perbellini F, Watson S, Scigliano M, Alayoubi S, Tkach S, Bardi I . Investigation of cardiac fibroblasts using myocardial slices. Cardiovasc Res. 2017; 114(1):77-89. PMC: 5852538. DOI: 10.1093/cvr/cvx152. View

16.

Huang D, Sherman B, Lempicki R . Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57. DOI: 10.1038/nprot.2008.211. View

17.

Masyuk A, Huang B, Radtke B, Gajdos G, Splinter P, Masyuk T . Ciliary subcellular localization of TGR5 determines the cholangiocyte functional response to bile acid signaling. Am J Physiol Gastrointest Liver Physiol. 2013; 304(11):G1013-24. PMC: 3680685. DOI: 10.1152/ajpgi.00383.2012. View

18.

Schafer S, Viswanathan S, Widjaja A, Lim W, Moreno-Moral A, DeLaughter D . IL-11 is a crucial determinant of cardiovascular fibrosis. Nature. 2017; 552(7683):110-115. PMC: 5807082. DOI: 10.1038/nature24676. View

19.

Cojan-Minzat B, Zlibut A, Agoston-Coldea L . Non-ischemic dilated cardiomyopathy and cardiac fibrosis. Heart Fail Rev. 2020; 26(5):1081-1101. DOI: 10.1007/s10741-020-09940-0. View

20.

Sanchez-Garcia A, Sahebkar A, Simental-Mendia M, Simental-Mendia L . Effect of ursodeoxycholic acid on glycemic markers: A systematic review and meta-analysis of clinical trials. Pharmacol Res. 2018; 135:144-149. DOI: 10.1016/j.phrs.2018.08.008. View